Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE‐3 (Recombinant Human INsulin Equivalence‐3) study

AIM: To establish the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of proposed biosimilar insulin 70/30 (Biocon's Insulin‐70/30) and HUMULIN® 70/30 (HUMULIN‐70/30; Eli Lilly and Company, IN). MATERIALS AND METHODS: In this phase 1, automated euglycaemic glucose clamp study, 78 heal...

Descripción completa

Detalles Bibliográficos
Autores principales: Plum‐Mörschel, Leona, Klein, Oliver, Singh, Gursharan, Murugesan, Sundara Moorthi Nainar, Marwah, Ashwani, Sharma, Nirant, Panda, Jayanti, Loganathan, Subramanian, Lakshmi, Gopu Chandrasekharan, Athalye, Sandeep N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543887/
https://www.ncbi.nlm.nih.gov/pubmed/35589611
http://dx.doi.org/10.1111/dom.14768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543887/
https://www.ncbi.nlm.nih.gov/pubmed/35589611
http://dx.doi.org/10.1111/dom.14768

Ejemplares similares